VIDEO: Adding docetaxel up front improved survival in prostate cancer by more than a year

CHICAGO –The answer was nearly a decade in coming, but worth the wait: Adding docetaxel to initial hormonal therapy in men with metastatic, hormone-sensitive prostate cancer can extend overall survival by more than a year.

Dr. Christopher Sweeney of the Lank Center of Genitourinary Oncology at the Dana-Farber Cancer Institute, Boston, discusses the implications of the results before presenting the phase III study at the annual meeting of the American Society of Clinical Oncology.

The study was funded by the National Cancer Institute. Dr. Sweeney disclosed serving in consulting or advisory roles to Astellas Pharma, BIND Biosciences, and other companies. One of his coauthors disclosed consulting/advising or receiving research funding from Astellas, Bayer, and other companies, and another coauthor served as a Data and Safety Monitoring Board chair for Genentech and received research grants from Onyx Pharmaceuticals and Merck.

CHICAGO –The answer was nearly a decade in coming, but worth the wait: Adding docetaxel to initial hormonal therapy in men with metastatic, hormone-sensitive prostate cancer can extend overall survival by more than a year.

Dr. Christopher Sweeney of the Lank Center of Genitourinary Oncology at the Dana-Farber Cancer Institute, Boston, discusses the implications of the results before presenting the phase III study at the annual meeting of the American Society of Clinical Oncology.

The study was funded by the National Cancer Institute. Dr. Sweeney disclosed serving in consulting or advisory roles to Astellas Pharma, BIND Biosciences, and other companies. One of his coauthors disclosed consulting/advising or receiving research funding from Astellas, Bayer, and other companies, and another coauthor served as a Data and Safety Monitoring Board chair for Genentech and received research grants from Onyx Pharmaceuticals and Merck.

CHICAGO –The answer was nearly a decade in coming, but worth the wait: Adding docetaxel to initial hormonal therapy in men with metastatic, hormone-sensitive prostate cancer can extend overall survival by more than a year.

Dr. Christopher Sweeney of the Lank Center of Genitourinary Oncology at the Dana-Farber Cancer Institute, Boston, discusses the implications of the results before presenting the phase III study at the annual meeting of the American Society of Clinical Oncology.

The study was funded by the National Cancer Institute. Dr. Sweeney disclosed serving in consulting or advisory roles to Astellas Pharma, BIND Biosciences, and other companies. One of his coauthors disclosed consulting/advising or receiving research funding from Astellas, Bayer, and other companies, and another coauthor served as a Data and Safety Monitoring Board chair for Genentech and received research grants from Onyx Pharmaceuticals and Merck.